BD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion

Medical technology company BD has announced its definitive agreement to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion in cash. Critical Care, a global leader in advanced monitoring solutions, is a high-growth industry leader with advanced AI algorithms used by millions of patients worldwide.

The acquisition is expected to enhance BD's portfolio of smart connected care solutions. BD anticipates the acquisition to be immediately accretive to all key financial measures and is expected to close before the end of the calendar year, subject to customary regulatory reviews and closing conditions.

Upon closing, Critical Care will operate as a separate business unit within BD's Medical segment, maintaining its presence in Irvine, California. Katie Szyman, the corporate vice president of Critical Care, will lead the new business unit within BD.

BD expects to fund the all-cash transaction with approximately $1 billion of cash and $3.2 billion of new debt. The company aims to de-lever to its 2.5x long-term net leverage target within 12 to 18 months of closing.